In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

Show full item record



Permalink

http://hdl.handle.net/10138/224428

Citation

Laukkanen , S , Gronroos , T , Polonen , P , Kuusanmaki , H , Mehtonen , J , Cloos , J , Ossenkoppele , G , Gjertsen , B , Oystein , B , Heckman , C , Heinaniemi , M , Kontro , M & Lohi , O 2017 , ' In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL ' , Blood cancer journal , vol. 7 , 604 . https://doi.org/10.1038/bcj.2017.87

Title: In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
Author: Laukkanen, S.; Gronroos, T.; Polonen, P.; Kuusanmaki, H.; Mehtonen, J.; Cloos, J.; Ossenkoppele, G.; Gjertsen, B.; Oystein, B.; Heckman, C.; Heinaniemi, M.; Kontro, M.; Lohi, O.
Other contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, University of Helsinki
University of Helsinki, Clinicum





Date: 2017-09-08
Language: eng
Number of pages: 4
Belongs to series: Blood cancer journal
ISSN: 2044-5385
DOI: https://doi.org/10.1038/bcj.2017.87
URI: http://hdl.handle.net/10138/224428
Subject: ACUTE LYMPHOBLASTIC-LEUKEMIA
CELL-ACTIVATION
KINASE INHIBITOR
SENSITIVITY
EXPERIENCE
REMISSION
PATIENT
LCK
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
bcj201787a.pdf 669.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record